VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RAPP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RAPPRapport Therapeutics, Inc. Common Stock
$23.40$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRAPPFinancials

Rapport Therapeutics, Inc. Common Stock (RAPP) Income Statement

4Y historyFree accessUpdated daily

Revenue is effectively absent across most of the ten reported quarters, with the lone $20.0M 2026Q1 quarter producing a 100% gross margin that was overwhelmed by a -121.1% operating margin and -99.3% net margin, indicating the income statement reflects R&D-driven losses rather than any margin trajectory.

Income StatementBalance SheetCash FlowRatios

RAPP Income Statement

Annual statement

RAPP Income Statement

Rapport Therapeutics, Inc. Common Stock (RAPP) annual income statement — 4-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22
Sales/Revenue20M0000
Revenue Growth %-----
Cost of Goods Sold000015K
COGS % of Revenue-----
Gross Profit20M000-15K
Gross Margin %100%----
Gross Profit Growth %---100%-
Operating Expenses187.62M125.1M83.06M36.18M10.35M
OpEx % of Revenue-----
Selling, General & Admin38.91M30.31M22.12M8.18M1.37M
SG&A % of Revenue-----
Research & Development148.7M94.79M60.94M28M9.12M
R&D % of Revenue-----
Other Operating Expenses0000-128.82K
Operating Income-167.62M-125.1M-83.06M-36.18M-10.37M
Operating Margin %-838.08%----
Operating Income Growth %--50.62%-129.57%-248.98%-
EBITDA-166.71M-124.08M-82.22M-36.07M-10.35M
EBITDA Margin %-833.57%----
EBITDA Growth %-52.81%-50.92%-127.95%-248.41%-
D&A (Non-Cash Add-back)902K1.02M839K112K15K
EBIT-159.57M-125.1M-83.06M-34.78M-10.37M
Net Interest Income17.15M13.62M12.14M2.53M-285K
Interest Income17.15M13.62M12.14M2.53M0
Interest Expense0000285K
Other Income/Expense17.15M13.62M4.75M1.4M-285K
Pretax Income-150.47M-111.48M-78.31M-34.78M-10.65M
Pretax Margin %-752.35%----
Income Tax00010K0
Effective Tax Rate %0%0%0%-0.03%0%
Net Income-150.47M-111.48M-78.31M-34.79M-10.65M
Net Margin %-752.35%----
Net Income Growth %-54.01%-42.37%-125.11%-226.57%-
Net Income (Continuing)-150.47M-111.48M-78.31M-34.79M-10.65M
Discontinued Operations00000
Minority Interest00000
EPS (Diluted)-3.15-2.86-3.78-23.10-0.29
EPS Growth %-16.97%24.34%83.64%-7865.52%-
EPS (Basic)--2.86-3.78-23.10-0.29
Diluted Shares Outstanding47.77M38.93M20.74M1.51M20.12M
Basic Shares Outstanding47.77M38.93M20.74M1.51M20.12M
Dividend Payout Ratio-----

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetHealthy
Cash FlowBurning
Top Statement Risk

Pivotal trial funding dependence

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Revenue Absent, Losses Scaling With R&D

Based on the reported quarterly income statement, RAPP recorded no product revenue across most of the ten quarters, with a single $20.0M quarter in 2026Q1 that appears non-recurring and does not establish a growth trend.

The reported figures suggest the company remains a pre-revenue clinical-stage business, so conventional growth rates are not meaningful here. The lone revenue quarter likely reflects a collaboration or milestone-type receipt rather than durable sales, which warrants further investigation before it is treated as a base for projection. Investors should monitor whether future quarters show recurring receipts, since the cost base is expanding independently of any top-line build.

Operating Losses Widening Faster Than Overhead

Reported R&D expense rose from roughly $15.5M in 2024Q3 to $51.4M in 2026Q2, while SG&A stayed comparatively contained near $6M to $11M, indicating operating losses are driven almost entirely by clinical spend.

The divergence between R&D growth and SG&A stability suggests that the cost base is tied to trial execution rather than to a scalable commercial infrastructure. Operating losses that grew from about $21.6M to over $60M imply negative operating leverage in the near term, since no revenue offsets the expanding spend. This pattern appears consistent with a company prioritizing pivotal-stage development over overhead efficiency.

Net Losses Reflect Burn, Not Accounting Noise

Net losses track operating losses closely, and reported stock-based compensation of $7.6M in 2026Q3 and $7.2M in 2026Q2 represents a non-cash drag that is modest relative to the roughly $40M to $57M net losses in those quarters.

Because net income is essentially operating loss with minimal non-operating offset, the headline loss is a fair reflection of cash-consuming activity rather than an accounting distortion. Stock-based compensation is material but not dominant, so adjusting for it would narrow the loss only modestly. The quarterly EPS swings, such as -0.42 in 2026Q1 against -1.19 in 2026Q2, appear driven by share count dynamics and lumpy trial costs rather than by changes in underlying earnings quality.

R&D Dominates a Lean Overhead Structure

According to reported financials, R&D accounted for the large majority of total operating expense in recent quarters, with 2026Q2 R&D of $51.4M against SG&A of $9.4M, implying roughly 85 percent of spend tied to clinical programs.

The cost structure is clearly concentrated in development, which fits a company advancing RAP-219 through pivotal-stage work. SG&A has remained within a narrow band, suggesting management is holding administrative expansion in check while trial spend scales. Investors should watch whether R&D continues to rise into pivotal readouts, since that trajectory determines how quickly the company will need additional capital.

Burn Rate Outpaces Visible Funding Support

The strongest challenge is that quarterly operating losses above $40M, with no offsetting revenue, may outpace the disclosed $52.6M cash figure, which suggests equity dilution is a plausible near-term path rather than a remote risk.

If the reported $52.6M cash position is accurate and recent quarterly losses approach $40M to $60M, the visible runway appears short relative to pivotal trial timelines. This analytical inference points to a financing event, but the available data does not confirm current liquidity, so the conclusion warrants further investigation against the latest balance sheet. Binary sensitivity to trial readouts is elevated, and a financing that occurs before data could compress valuation.

RAPP — Frequently Asked Questions

Quick answers to the most common questions about buying RAPP stock.

What was Rapport Therapeutics, Inc. Common Stock's (RAPP) revenue in 2025?

For fiscal year 2025, Rapport Therapeutics, Inc. Common Stock (RAPP) reported total revenue of $0.0M.

Is Rapport Therapeutics, Inc. Common Stock (RAPP) profitable?

Rapport Therapeutics, Inc. Common Stock (RAPP) reported a net loss of $111.5M for the fiscal year ending 2025.